https://www.imidomics.com https://www.imidomics.com/about https://www.imidomics.com/careers https://www.imidomics.com/contact https://www.imidomics.com/cookie-policy https://www.imidomics.com/news https://www.imidomics.com/partnerships https://www.imidomics.com/pipeline https://www.imidomics.com/science https://www.imidomics.com/privacy https://www.imidomics.com/search https://www.imidomics.com/news/a-combined-transcriptomic-and-genomic-analysis-identifies-a-gene-signature-associated-with-the-response-to-anti-tnf-therapy-in-rheumatoid-arthritis https://www.imidomics.com/news/a-cross-disease-meta-gwas-identifies-four-new-susceptibility-loci-shared-between-systemic-sclerosis-and-crohns-disease https://www.imidomics.com/news/a-questionnaire-based-study-on-contraceptive-practice-in-patients-with-rheumatic-disease-found-no-significant-difference-in-age-matched-healthy-controls https://www.imidomics.com/news/age-dependent-impact-of-the-major-common-genetic-risk-factor-for-covid-19-on-severity-and-mortality https://www.imidomics.com/news/arnapipe-a-balanced-efficient-and-distributed-pipeline-for-processing-rna-seq-data-in-high-performance-computing-environments https://www.imidomics.com/news/cardiovascular-disease-in-immune-mediated-inflammatory-diseases-a-cross-sectional-analysis-of-6-cohorts https://www.imidomics.com/news/cataloniabio-healthtech-has-awarded-imidomics-with-the-bioexit-award-award-acceptance-speech-by-co-founder-and-cmo-dr-sara-marsal https://www.imidomics.com/news/complement-genes-contribute-sex-biased-vulnerability-in-diverse-disorders https://www.imidomics.com/news/detailed-stratified-gwas-analysis-for-severe-covid-19-in-four-european-populations https://www.imidomics.com/news/doctis-article-in-magazine-eu-research https://www.imidomics.com/news/doctis-in-the-final-stretch-to-revolutionize-the-treatment-of-immune-mediated-inflammatory-diseases https://www.imidomics.com/news/dra-sara-marsal-recognized-among-the-10-most-valued-in-rheumatology-by-diario-abc https://www.imidomics.com/news/drug-candidate-for-severe-covid-19-identified-by-imidomics-and-vhir-rheumatology-group-selected-for-nih-clinical-trial https://www.imidomics.com/news/epigenome-wide-association-study-of-rheumatoid-arthritis-identifies-differentially-methylated-loci-in-b-cells https://www.imidomics.com/news/exclusive-formation-licenses-first-drug-since-372m-raise-eyes-more-deals-in-2025 https://www.imidomics.com/news/food-groups-associated-with-imids-mendelian-randomization-and-disease-severity-study https://www.imidomics.com/news/food-groups-associated-with-imids-mendelian-randomization-and-disease-severity-study-2 https://www.imidomics.com/news/formation-bio-licenses-first-in-class-anti-cd226-autoimmune-program-from-imidomics https://www.imidomics.com/news/founder-of-imidomics-receives-the-trifermed-award-for-social-impact-in-healthcare https://www.imidomics.com/news/functional-rare-variants-influence-the-clinical-response-to-anti-tnf-therapy-in-crohns-disease https://www.imidomics.com/news/genetic-association-between-cd96-locus-and-immunogenicity-to-anti-tnf-therapy-in-crohns-disease https://www.imidomics.com/news/genetic-variation-associated-with-cardiovascular-risk-in-autoimmune-diseases https://www.imidomics.com/news/genetic-variation-at-the-glycosaminoglycan-metabolism-pathway-contributes-to-the-risk-of-psoriatic-arthritis-but-not-psoriasis https://www.imidomics.com/news/genetic-variation-at-the-glycosaminoglycan-metabolism-pathway-contributes-to-the-risk-of-psoriatic-arthritis-but-not-psoriasis-2 https://www.imidomics.com/news/genome-wide-association-study-meta-analysis-identifies-five-new-loci-for-systemic-lupus-erythematosus https://www.imidomics.com/news/genome-wide-pathway-analysis-identifies-vegf-pathway-association-with-oral-ulceration-in-systemic-lupus-erythematosus https://www.imidomics.com/news/genomewide-association-study-of-severe-covid-19-with-respiratory-failure https://www.imidomics.com/news/https-onlinelibrary-wiley-com-doi-abs-10-1111-iji-12609 https://www.imidomics.com/news/human-leukocyte-antigen-signatures-as-pathophysiological-discriminants-of-microscopic-colitis-subtypes https://www.imidomics.com/news/imidomics-and-bristol-myers-squibb-expand-long-standing-partnership-to-advance-immune-mediated-inflammatory-disease-treatment-research-and-development https://www.imidomics.com/news/imidomics-and-gossamer-bio-enter-into-a-strategic-collaboration-to-advance-the-development-of-novel-treatments-for-patients-with-immune-mediated-inflammatory-diseases https://www.imidomics.com/news/imidomics-announces-appointment-of-key-science-and-medical-research-experts-to-newly-formed-immunology-advisory-board https://www.imidomics.com/news/imidomics-announces-strategic-agreement-with-wuxi-biologics-to-advance-imb1001-antibody-development-for-immune-mediated-inflammatory-diseases https://www.imidomics.com/news/imidomics-co-organizes-symposium-combination-therapies-in-common-diseases-clinical-and-translational-challenges https://www.imidomics.com/news/imidomics-establishes-a-license-and-collaboration-partnership-with-the-university-of-barcelona-to-advance-treatments-for-imids https://www.imidomics.com/news/imidomics-funds-a-study-that-identifies-a-new-drug-candidate-to-prevent-severe-covid-19 https://www.imidomics.com/news/imidomics-granted-horizon-2020-project-on-systems-approaches-for-the-discovery-of-combinatorial-therapies-for-complex-disorders https://www.imidomics.com/news/imidomics-inc-announces-strategic-investment-from-drug-discovery-and-research-leader-evotec-se https://www.imidomics.com/news/imidomics-inc-appoints-life-sciences-industry-leader-matthias-evers-ph-d-to-board-of-directors https://www.imidomics.com/news/imidomics-inc-secures-exclusive-worldwide-licensing-agreement-with-tnax-biopharma-corporation-for-tnax101a-imb1001-a-promising-drug-candidate-for-immune-mediated-inflammatory-diseases https://www.imidomics.com/news/imidomics-sponsors-the-online-symposium-combination-therapies-in-common-diseases-clinical-and-translational-challenges-october-7th-2021 https://www.imidomics.com/news/imidomics-strengthens-its-leadership-with-the-addition-of-dr-eric-perakslis-to-its-executive-team-and-dr-ramon-felciano-to-its-advisory-team https://www.imidomics.com/news/imidomics-tm-announces-scientific-and-business-advisory-boards https://www.imidomics.com/news/imidomics-tm-closes-16-5-million-series-a-financing-to-advance-its-precision-discovery-platform-for-immune-mediated-inflammatory-diseases https://www.imidomics.com/news/incidence-of-covid-19-in-a-cohort-of-adult-and-paediatric-patients-with-rheumatic-diseases-treated-with-targeted-biologic-and-synthetic-disease-modifying-anti-rheumatic-drugs https://www.imidomics.com/news/influenza-adverse-events-in-patients-with-rheumatoid-arthritis-ulcerative-colitis-or-psoriatic-arthritis-in-the-tofacitinib-clinical-development-programs https://www.imidomics.com/news/interactions-between-rheumatoid-arthritis-antibodies-are-associated-with-the-response-to-anti-tumor-necrosis-factor-therapy https://www.imidomics.com/news/interactions-between-rheumatoid-arthritis-antibodies-are-associated-with-the-response-to-anti-tumor-necrosis-factor-therapy-2 https://www.imidomics.com/news/leveraging-molecular-data-analysis-to-understand-drug-response-in-systemic-sclerosis https://www.imidomics.com/news/longitudinal-analysis-of-blood-dna-methylation-identifies-mechanisms-of-response-to-tumor-necrosis-factor-inhibitor-therapy-in-rheumatoid-arthritis https://www.imidomics.com/news/lower-peripheral-helper-t-cell-levels-in-the-synovium-are-associated-with-a-better-response-to-anti-tnf-therapy-in-rheumatoid-arthritis https://www.imidomics.com/news/mapping-the-human-genetic-architecture-of-covid-19 https://www.imidomics.com/news/retention-of-subcutaneous-abatacept-for-the-treatment-of-rheumatoid-arthritis-real-world-results-from-the-ascore-study-an-international-2-year-observational-study https://www.imidomics.com/news/seven-chain-adaptive-immune-receptor-repertoire-analysis-in-rheumatoid-arthritis-reveals-novel-features-associated-with-disease-and-clinically-relevant-phenotypes https://www.imidomics.com/news/targeting-of-the-cd80-86-proinflammatory-axis-as-a-therapeutic-strategy-to-prevent-severe-covid-19 https://www.imidomics.com/news/targeting-of-the-cd80-86-proinflammatory-axis-as-a-therapeutic-strategy-to-prevent-severe-covid-19-20 https://www.imidomics.com/news/toward-precision-medicine-in-atopic-dermatitis-using-molecular-based-approaches https://www.imidomics.com/news/twist-bioscience-and-imidomics-collaborate-to-discover-antibodies-for-applications-in-immune-mediated-inflammatory-diseases https://www.imidomics.com/news/ucb-announces-strategic-investment-in-imidomics-inc-to-advance-breakthrough-solutions-for-immune-mediated-inflammatory-diseases https://www.imidomics.com/news/we-are-proud-to-be-recognized-in-ucbs-2024-integrated-annual-report-highlighting-the-impact-of-our-partnership-in-shaping-the-future-of-imid-treatment